References
- Attele AS, Wu JA, Yuan CS. (1999). Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol, 58, 1685–1693.
- Braunwald E, Kloner RA. (1985). Myocardial reperfusion: A double-edged sword? J Clin Invest, 76, 1713–1719.
- de Gusmão FM, Becker C, Carvalho MH, Barros LF. (2005). Angiotensin II inhibition during myocardial ischemia-reperfusion in dogs: Effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity and left ventricular ejection fraction. Int J Cardiol, 100, 363–370.
- Haiyun L, Yijia L, Honggang L, Honghai W. (2004). Protective effect of total flavones from Elsholtzia blanda (TFEB) on myocardial ischemia induced by coronary occlusion in canines. J Ethnopharmacol, 94, 101–107.
- Ji LL, Stratman FW, Lardy HA. (1988). Antioxidant enzyme systems in rat liver and skeletal muscle. Influences of selenium deficiency, chronic training, and acute exercise. Arch Biochem Biophys, 263, 150–160.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem, 193, 265–275.
- McCord JM, Fridovich I. (1969). Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem, 244, 6049–6055.
- Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. (2005). Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol, 100, 179–190.
- Neves LA, Almeida AP, Khosla MC, Campagnole-Santos MJ, Santos RA. (1997). Effect of angiotensin-(1-7) on reperfusion arrhythmias in isolated rat hearts. Braz J Med Biol Res, 30, 801–809.
- Niccoli G, Burzotta F, Galiuto L, Crea F. (2009). Myocardial no-reflow in humans. J Am Coll Cardiol, 54, 281–292.
- Ohkawa H, Ohishi N, Yagi K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem, 95, 351–358.
- Ozdemir R, Parlakpinar H, Polat A, Colak C, Ermis N, Acet A. (2006). Selective endothelin a (ETA) receptor antagonist (BQ-123) reduces both myocardial infarct size and oxidant injury. Toxicology, 219, 142–149.
- Wang T, Yu XF, Qu SC, Xu HL, Sui DY. (2010). Ginsenoside Rb3 inhibits angiotensin II-induced vascular smooth muscle cells proliferation. Basic Clin Pharmacol Toxicol, 107, 685–689.
- Wang Z, Li M, Wu WK, Tan HM, Geng DF. (2008). Ginsenoside Rb1 preconditioning protects against myocardial infarction after regional ischemia and reperfusion by activation of phosphatidylinositol-3-kinase signal transduction. Cardiovasc Drugs Ther, 22, 443–452.
- Xie JT, Shao ZH, Vanden Hoek TL, Chang WT, Li J, Mehendale S, Wang CZ, Hsu CW, Becker LB, Yin JJ, Yuan CS. (2006). Antioxidant effects of ginsenoside Re in cardiomyocytes. Eur J Pharmacol, 532, 201–207.
- Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen CJ. (2004). Molecular mechanisms and clinical applications of ginseng root for cardiovascular disease. Med Sci Monit, 10, RA187–RA192.